| Allogeneic Hematopoietic Stem Cell Transplantation (NCT00750126) | University Hospital, Clermont-Ferrand | 2007-04-01 |
| Effects of OM-174 in Adult Patients With Solid Tumors (NCT01800812) | Centre Hospitalier Universitaire Dijon | 2007-03-01 |
| Characterisation of Gene Variants in the Angiogenic Pathway (NCT00716287) | National University Hospital, Singapore | 2007-03-01 |
| Karenitecin in Pediatric Patients With Refractory or Recurrent Solid Tumors N10010) (NCT00586560) | Baylor College of Medicine | 2007-02-01 |
| Effect of Different Doses of AMG 706 on the Gallbladder in Advanced Solid Tumors (NCT00448786) | Amgen | 2007-02-01 |
| Gemcitabine and Dasatinib in Advanced Solid Tumors (NCT00429234) | M.D. Anderson Cancer Center | 2007-01-01 |
| Bevacizumab and Bortezomib in Patients With Advanced Malignancy (NCT00428545) | M.D. Anderson Cancer Center | 2007-01-01 |
| Anti-EGFR Immunoliposomes in Solid Tumors (NCT01702129) | University Hospital, Basel, Switzerland | 2007-01-01 |
| Tabectedin to Treat Children and Adolescents With Cancer (NCT01453283) | National Cancer Institute (NCI) | 2006-12-20 |
| A Phase I Trial of Nelfinavir (Viracept ) in Adults With Solid Tumors (NCT01445106) | National Cancer Institute (NCI) | 2006-12-11 |
| Study to Assess Safety of AZD7762 Administered Alone and in Combination With Gemcitabine in Patients With Advanced Solid Malignancies (NCT00413686) | AstraZeneca | 2006-12-01 |
| QUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid Tumors (NCT00974896) | NantCell, Inc. | 2006-12-01 |
| Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC) (NCT00413283) | Amgen | 2006-12-01 |
| Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies (NCT00420615) | Novartis Pharmaceuticals | 2006-12-01 |
| Study of IMC-3G3 in Patients With Tumors That Are Not Responding to Standard Therapies or No Therapy is Available (NCT00768391) | Eli Lilly and Company | 2006-12-01 |
| Phase 1 Study Of Aurora Kinase Inhibitor PF-03814735 In Patients With Advanced Solid Tumors (NCT00424632) | Pfizer | 2006-11-01 |
| Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors (NCT00551512) | CanBas Co. Ltd. | 2006-11-01 |
| Effect of Ketoconazole Inhibition of CYP3A on Urinary Excretion of Docetaxel (NCT00697437) | National University Hospital, Singapore | 2006-10-01 |
| Biodistribution and Dosimetry of Serial PET Imaging With Ga-68 Labeled F(ab') 2- Trastuzumab (NCT00613847) | Memorial Sloan Kettering Cancer Center | 2006-10-01 |
| Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies (NCT00629200) | M.D. Anderson Cancer Center | 2006-09-13 |
| Pharmacokinetics of Patupilone After a Single Intravenous Administration in Patients With Advance Solid Tumor Malignancies. (NCT00426140) | Novartis Pharmaceuticals | 2006-08-01 |
| Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6) (NCT00871663) | Merck Sharp & Dohme LLC | 2006-08-01 |
| AS703569 Phase I in Patients With Solid Tumours (NCT00391521) | EMD Serono | 2006-08-01 |
| Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer (NCT01538537) | Traws Pharma, Inc. | 2006-08-01 |
| Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer (NCT01538563) | Traws Pharma, Inc. | 2006-06-01 |
| CDDO to Treat Solid Tumors and Lymphomas (NCT00322140) | National Cancer Institute (NCI) | 2006-05-01 |
| A Phase I Study of Zalypsis (PM00104) in Subjects With Advanced Malignant Solid Tumors or Lymphoma (NCT00359294) | PharmaMar | 2006-05-01 |
| Target Dosing of Docetaxel Through Pharmacokinetic/Pharmacodynamic Optimisation of the First Chemotherapeutic Cycle (NCT00703378) | National University Hospital, Singapore | 2006-05-01 |
| RTA 402 in Advanced Solid Tumors or Lymphoid Malignancies (NCT00508807) | M.D. Anderson Cancer Center | 2006-04-01 |
| Dose-escalation Study of Gimatecan Administered in Two Different Schedules in Adult Patients With Advanced Solid Tumors (NCT00420485) | Novartis Pharmaceuticals | 2006-03-01 |
| An Open Label Treatment Extension Study of AMG 706 (NCT00360867) | Amgen | 2005-12-01 |
| Peritumoral Injection of Immature Dendritic Cells to Irradiated Skin Metastases of Solid Tumors (NCT00278018) | Hadassah Medical Organization | 2005-12-01 |
| Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin (NCT00773344) | Bristol-Myers Squibb | 2005-12-01 |
| Pulmonary Function at Presentation and Follow-up in Hemato-Oncology 3-7 Years Old Children (NCT00552825) | Sheba Medical Center | 2005-10-01 |
| A Phase I Study of ABT-510 in Combination With Bevacizumab in Advanced Solid Tumors (NCT00586092) | Herbert Hurwitz | 2005-09-01 |
| Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants (NCT00606437) | Duke University | 2005-09-01 |
| A Phase I Study of PM02734 in Subjects With Advanced Malignant Solid Tumors (NCT00404521) | PharmaMar | 2005-08-01 |
| Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer (NCT00101582) | Swedish Orphan Biovitrum | 2005-08-01 |
| AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin (NCT00147225) | M.D. Anderson Cancer Center | 2005-08-01 |
| Redosing With CP-870, 893 in Patients With Clinical Benefit After a Single Infusion From A Phase I, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors (NCT02157831) | Abramson Cancer Center at Penn Medicine | 2005-07-01 |
| Safety Study of OXi4503 (a Vascular Disrupting Agent) Given by 3 x Weekly Intravenous Infusions to Patients With Advanced Solid Tumors (NCT00977210) | Mateon Therapeutics | 2005-07-01 |
| A Phase I Trial of ZIO-101 in Solid Tumors (NCT00591396) | Alaunos Therapeutics | 2005-07-01 |
| Phase I Trial of ZIO-101 in Patients With Solid Tumors (NCT00509782) | M.D. Anderson Cancer Center | 2005-05-01 |
| A Study To Find The Best Doses Of SU011248 (Sunitinib) And Capecitabine When These Drugs Are Administered Together (NCT00618124) | Pfizer | 2005-05-01 |
| Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath (NCT00578942) | David Rizzieri, MD | 2005-05-01 |
| AZD1152 in Patients With Advanced Solid Malignancies-Study 1 (NCT00497731) | AstraZeneca | 2005-05-01 |
| Study Of Advanced Gastrointestinal Malignancies And Other Solid Tumors (NCT00660426) | Washington University School of Medicine | 2005-03-01 |
| A Study To Find The Best Doses Of SU011248 And Gemcitabine When Given Together To Patients With Advanced Solid Tumors (NCT00615446) | Pfizer | 2005-03-01 |
| A Pharmacokinetic Study of Oral Cyclophosphamide and Topotecan in Children With Recurrent Solid Tumors (NCT00628732) | Children's Medical Center Dallas | 2005-01-01 |
| Safety/Tolerance Study of PPI-2458 in Subjects With Non-Hodgkin's Lymphoma and Solid Tumors (NCT00100347) | PRAECIS Pharmaceuticals Inc. | 2004-12-01 |
| Concurrent Xeloda and Radiotherapy for Bone Metastases (NCT00192777) | Rambam Health Care Campus | 2004-11-01 |
| Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors (NCT00091806) | Amgen | 2004-08-01 |
| Topotecan, Ifosfamide and Carboplatin in Children and Young Adults With Solid Tumors (NCT00502892) | M.D. Anderson Cancer Center | 2004-08-01 |
| Imatinib and PTK787/ZK222584 in Refractory and/or Advanced Solid Tumors (NCT00611689) | SCRI Development Innovations, LLC | 2004-07-01 |
| Study of Ixabepilone (BMS-247550) in Patients With Solid Tumors (NCT01018966) | R-Pharm | 2004-04-01 |
| Rollover Protocol for Prior SU011248 Protocols (NCT00798889) | Pfizer | 2004-03-01 |
| Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment (NCT00425204) | Amgen | 2004-03-01 |
| A Trial Of SU14813 In Patients With Advanced Solid Malignancies (NCT00982267) | Pfizer | 2003-12-01 |
| Study of Oral Clofarabine Administered Daily for 5 Days in Adult Patients With Refractory Solid Tumors (NCT00125827) | Genzyme, a Sanofi Company | 2003-10-01 |
| Study to Evaluate the Effect of Age (Geriatric) and Kidney Function on the Safety, Efficacy and Pharmacokinetics of OctreoScan in Patients Who Have New or Recurrent Tumors (NCT00944372) | Mallinckrodt | 2003-07-01 |
| Study of ZD1839 Combined With Irinotecan and Vincristine in Pediatric Patients With Refractory Solid Tumors (NCT00186979) | St. Jude Children's Research Hospital | 2003-05-01 |
| Phase I Study of Capecitabine in Combination With Cisplatin and Irinotecan (NCT00249977) | University of New Mexico | 2003-04-01 |
| Phase I Study of Indibulin in Patients With Solid Tumors (NCT00591136) | Alaunos Therapeutics | 2003-04-01 |
| Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials (NCT00828919) | Pfizer | 2003-03-07 |
| rhEndostatin Protein Involving Pediatric Patients With Cancer (NCT00165373) | Dana-Farber Cancer Institute | 2003-01-01 |
| Clofarabine in Adult Patients With Advanced Solid Tumors (NCT00125840) | Genzyme, a Sanofi Company | 2002-08-01 |
| Phase I Study of PN401, Fluorouracil, Leucovorin and CPT-11 in Patients With Solid Tumors (NCT00044785) | Wellstat Therapeutics | 2002-08-01 |
| CIBMTR Research Database (NCT01166009) | Center for International Blood and Marrow Transplant Research | 2002-07-01 |
| A Phase 1 Study of S-3304 in Patients With Solid Tumors (NCT00033215) | Shionogi | 2001-11-01 |
| Dose-finding Study of Novel Erythropoiesis Stimulating Protein (NESP) for the Treatment of Anaemia in Subjects With Solid Tumours Receiving Multicycle Chemotherapy (NCT00540384) | Amgen | 1999-07-01 |
| Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial (NCT02354612) | Tracon Pharmaceuticals Inc. | |
| Expanded Access Program for Avapritinib (NCT04714086) | Blueprint Medicines Corporation | |
| Expanded Access to Telisotuzumab Adizutecan (NCT05982873) | AbbVie | |
| GOAT; Phase I Open Label Study of CGTG-102, a GM-CSF Encoding Oncolytic Adenovirus, for Advanced Cancers (NCT01437280) | Baylor College of Medicine | |
| Afatinib (GILOTRIF®) in Patients Suffering From Tumors Harboring Neuregulin 1 (NRG1) Gene Alterations (Specifically NRG1 Gene Fusion-positive Advanced Solid Tumors) (NCT05107193) | Boehringer Ingelheim | |